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Clofarabine (Clo), ﬂudarabine (Flu), and busulfan (Bu) are used in pretransplantation conditioning therapy for
patients with myeloid leukemia. To further improve their efﬁcacy in FMS-like tyrosine kinase 3 internal
tandem duplications (FLT3-ITD)-positive acute myeloid leukemia (AML), we investigated their synergism
with sorafenib (Sor). Exposure of FLT3-ITDepositive MV-4-11 and MOLM 13 cells to BuþCloþFluþSor resulted
in synergistic cytotoxicity; no such synergism was observed in the FLT3-wild type THP-1 and KBM3/
Bu2506 cell lines. The drug synergism in MV-4-11 cells could be attributed to activation of DNA damage
response, histone 3 modiﬁcations, inhibition of prosurvival kinases, and activation of apoptosis. Further, the
phosphorylation of kinases, including FLT3, MAPK kinase (MEK), and AKT, was inhibited. The FLT3-ITD
substrate STAT5 and its target gene PIM 2 product decreased when cells were exposed to Sor alone, Buþ-
CloþFlu, and BuþCloþFluþSor. The level of the proapoptotic protein p53 upregulated modulator of apoptosis
(PUMA) increased, whereas the level of prosurvival protein MCL-1 decreased when cells were exposed to
BuþCloþFluþSor. The interactions of PUMA with MCL-1 and/or BCL-2 were enhanced when cells were
exposed to BuþCloþFlu or BuþCloþFluþSor. The changes in the level of these proteins, which are involved in
mitochondrial control of apoptosis, correlate with changes in mitochondrial membrane potential. Buþ
CloþFluþSor decreased mitochondrial membrane potential by 60% and caused leakage of cytochrome c,
second mitochondria-derived activator of caspases (SMAC)/direct IAP Binding protein with low pI (DIABLO),
and AIF from the mitochondria to the cytoplasm, caspase activation, and cell death, suggesting the activation
of apoptosis. Analogous, synergistic cytotoxicity in response to Bu, Clo, Flu, and Sor was observed in
mononuclear cells isolated from FLT3-ITDepositive AML patients. Although our previous studies were aimed
at standardizing the conditioning regimen, the new ﬁndings suggest that patients with abnormal expression
of FLT3 might further beneﬁt from individualizing treatment through the addition of Sor to BuþCloþFlu,
thereby providing personalized pretransplantation therapy.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Approximately 30% of adults and 15% of children with
acute myeloid leukemia (AML) have evidence of mutations
that activate the FMS-like tyrosine kinase 3 (FLT3). These
important internal tandem duplications (ITDs) are detected
in leukemic cells at diagnosis; they are associated with an
increased risk for relapse after initial response todgments on page 1694.
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ty for Blood and Marrow Transplantation.chemotherapy and correlate with reduced overall survival of
the affected patient population. In addition to the mutant
forms, wild type (wt)eFLT3 is highly expressed in cells from a
large fraction of AML patients. Both mutant forms and
overexpressed wt-FLT3 have similar sensitivity to small-
molecule FLT3 inhibitors [1,2]. Tyrosine kinase inhibitors
that target FLT3 are in various stages of preclinical and clin-
ical development [3-5]. One such tyrosine kinase inhibitor,
sorafenib (Sor), has demonstrated potent activity against
FLT3-ITDepositive leukemia cells [6-14]. However, recent
phase I and II clinical studies showed that, in spite of its
ability to suppress the activity of this mutated kinase, Sor
resistance rapidly developed [7,8,15,16]. The results from
these studies suggested that the clinical efﬁcacy of Sor may
G. Song et al. / Biol Blood Marrow Transplant 20 (2014) 1687e16951688be better utilized if it is combined with cytotoxic agents that
have different mechanisms of action. Thus, Inaba et al. [17]
reported that a combination of Sor with clofarabine (Clo)
and cytarabine was highly active in relapsed/refractory pe-
diatric AML. These ﬁndings were recently conﬁrmed by
Fontanelli et al. [18], who reported that a combination of Sor
with Clo and cytarabine in patients with relapsed/refractory
FLT3-ITDepositive AML yielded morphologic complete
remission in a fraction of patients. These studies further
suggested that synergistic cytotoxicity may be achieved
when Sor is combined with other antileukemic agents.
The nucleoside analogs Clo and ﬂudarabine (Flu), and the
DNA alkylating agent busulfan (Bu) are increasingly used
as pretransplantation conditioning therapy in allogeneic
hematopoietic stem cell transplantation. These combinations
activate DNA damage response, induce histone modiﬁca-
tions, and lead to cell cycle checkpoint activation and
apoptosis [19-21]. A combination of these 3 drugs also con-
tributes to increased antileukemic efﬁcacy/patient beneﬁt
without an apparent concomitant increase in clinical normal
organ toxicity [22]. Taken all together, we hypothesized that
Sor in combination with Bu, Clo, and Flu would invoke
further synergistic cytotoxic activity in human myeloid
FLT3-ITDepositive leukemia cells.
We now report that the combination of Sor with Buþ-
CloþFlu provides synergistic cytotoxicity in FLT3-
ITDepositive AML cells. Biochemical analyses suggest that
this enhanced cytotoxicity may be attributed to activated
DNA damage response, histone 3 modiﬁcations, inhibition of
various tyrosine kinases and their downstream substrates,
and activation of the intrinsic apoptosis pathway. In addition
to providing a mechanistic explanation for the observed
synergistic cytotoxicity, we suggest that the results offer a
rationale for modifying the nucleoside analog Bu pre-
transplantation conditioning platform. Our previous studies
were aimed at standardizing the conditioning regimen; this
new development is aimed at further individualizing con-
ditioning therapy for patients with FLT3-ITD mutations and
with upregulated wt-FLT3 expression, such that inclusion of
Sor in the conditioning regimen would enhance efﬁcacy
without increased clinical normal organ toxicity.
MATERIALS AND METHODS
Reagents
Bu, Flu (Sigma-Aldrich, St. Louis, MO), and Sor (Selleck Chemicals,
Houston, TX) were dissolved in DMSO. Clo (Genzyme Corporation, Cam-
bridge, MA) was dissolved in PBS.
Cell Culture
The FLT3-ITDepositive MV-4-11 and FLT3-wt THP-1 AML cell lines used
in this study were obtained from the American Type Culture Collection
(Manassas, VA). MOLM 13 was kindly provided by Dr. Michael Andreeff’s
laboratory, and KBM3/Bu2506 is a Bu-resistant AML cell line developed in
our laboratory as previously described [23]. MV-4-11 cells were maintained
in Iscove’s modiﬁed Dulbecco’s medium, supplementedwith 10% FBS. THP-1
and KBM3/Bu2506 cells were grown in RPMI 1640 medium with 10% FBS,
whereasMOLM 13 cells were grown in RPMI 1640 mediumwith 20% FBS. All
growth media were supplemented with 100 U/mL of penicillin and 100 mg/
mL of streptomycin. The cells were maintained at 37C in a fully humidiﬁed
atmosphere of 5% CO2 in air.
Cytotoxicity and Apoptosis Assay
Cells (4  105 cells/mL) were exposed to Bu, Clo, Flu, and Sor alone, or
in combinations, for 48 hours. Cells were analyzed by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay [24].
All cytotoxicity data are expressed as the average  SD of at least 3
independent experiments.
Cell death by apoptosis after a 48-hour drug exposure was determined
by ﬂow cytometric measurements of phosphatidylserine externalization[25] with the Annexin-V-FLUOS (Roche Diagnostics, Indianapolis, IN) and by
using the 7-aminoactinomycin D kits (BD Biosciences, San Jose, CA), using a
MUSE Cell Analyzer (EMD Millipore, Billerica, MA).
Preparation of Cytosolic and Nuclear Protein Fractions
Control and drug-treated cells were collected and washed with ice-cold
PBS, resuspended in buffer A (10 mM HEPES [pH 7.6], 10 mM potassium
chloride, 100 mM EDTA, 100 mM ethylene glycol tetraacetic acid, 1 mM
dithiothreitol, 500 mM phenylmethylsulfonyl ﬂuoride with proteinase in-
hibitors) and incubated on ice for 30minutes. Cell disruptionwas completed
by passing the cells 10 times in a homogenizer on ice. Cell homogenates
were centrifuged at 800  g for 5 minutes at 4C to separate nuclei from
cytosolic fractions. The nuclear pellet was washed with ice-cold buffer A and
resuspended in lysis buffer B (20 mM HEPES [pH 7.6], 400 mM sodium
chloride, 100 mM EDTA, 100 mM ethylene glycol tetraacetic acid, 1 mM
dithiothreitol, and 500 mM phenylmethylsulfonyl ﬂuoride with proteinase
inhibitors). Particle-free cytosolic and nuclear lysates were obtained by
centrifugation at 15,000  g for 20 minutes at 4C.
Immunoprecipitation Analysis
Cells were incubated with drug(s) at 37C for 48 hours, centrifuged,
washed with ice-cold PBS, and lysed with cell lysis buffer. Protein concen-
trations were determined using a bicinchoninic acid Protein Assay kit
(Thermo Fisher Scientiﬁc, Inc., Rockford, IL). Cell lysate (450 mg total protein)
was diluted with ice-cold PBS to 500 mL, precleared by adding 50 mL of
Protein A/G bead slurry (Thermo Fisher Scientiﬁc, Inc.) and incubated at 4C
for 30 minutes with gentle mixing. The beads were removed by centrifu-
gation at 14,000  g at 4C for 10 minutes and the supernatant was trans-
ferred to a fresh centrifuge tube. An antibody (.6 mg) against p53 upregulated
modulator of apoptosis (PUMA) or MCL-1 was added to the supernatant and
gently rotated overnight at 4C. The immunocomplex was captured by
adding 50 mL of Protein A/G beads and incubated for 1 hour at 4C with
mixing. Unbound proteins in the supernatant were removed and the beads
were washed 4 times with cell lysis buffer. Bound proteins were eluted from
the beads with sodium dodecyl sulfate-polyacrylamide gel electrophoresis
sample buffer by boiling for 5 minutes and the immunoprecipitated samples
were analyzed by Western blot.
Western Blot Analysis
Cells were incubated with drug(s) at 37C for 48 hours, centrifuged,
washed with ice-cold PBS, lysed with cell lysis buffer, and protein concen-
trations were determined as described above. Western blot analysis was
done by resolving proteins in sodium dodecyl sulfate-polyacrylamide gel
electrophoresis gels, transferring onto nitrocellulose membranes, and
probing with primary antibodies. B-ACTIN and nucleoporin p62 were used
as internal controls for cytosolic and nuclear extracts, respectively. Signals
were detected using Immobilon Western Chemiluminescent horseradish
peroxidase substrate (EMD Millipore, Bedford, MA).
Analysis of Mitochondrial Transmembrane Potential
Changes in the mitochondrial transmembrane potential (DJm) were
measured using a JC-1 (5,50 ,6,60-tetrachloro-1,10,3,30-tetraethylbenzimida-
zolylcarbo cyanine iodide) mitochondrial membrane potential detection kit.
Cells were exposed to 1 mM valinomycin for 2 hours before incubation with
the JC-1 reagent as a positive control. Cells were incubated with the mito-
chondrial membrane potentialesensitive ﬂuorescent dye JC-1 for 20 mi-
nutes at 37C and then immediately analyzedwith ﬂowcytometry, using the
530-nm (FL-1 channel, green) and 585-nm (FL-2 channel, red) band-pass
ﬁlters simultaneously. Healthy cells with functional mitochondria and
high DJm exhibit red ﬂuorescence, whereas apoptotic or dying cells with
collapsed mitochondria or low DJm show green ﬂuorescence.
Analysis of Mitochondrial Death Factors Release
MV-4-11 cells were collected and washed with ice-cold PBS, resus-
pended in buffer A with proteinase inhibitors, and incubated on ice for
30 minutes. Cell disruptionwas completed by passing the cells 10 times in a
homogenizer. Cell homogenates were centrifuged at 800  g for 5 minutes
at 4C to separate nuclei from the mitochondrial and cytosolic fraction. The
mitochondrial and cytosolic fraction was further subjected to 8 minutes of
centrifugation at 12,500  g at 4C to pellet the mitochondria. The pelleted
mitochondria were washed with ice-cold buffer A and resuspended in 35 mL
of buffer containing 125 mM potassium chloride, 20 mM HEPES, tris(hy-
droxymethyl)aminomethane chloride, and 2 mM KH2PO4 (pH 7.2). Sor,
BuþCloþFlu, and BuþCloþFluþSor were added to the suspensions at con-
centrations used in the cytotoxicity assay. The concentration of DMSO in the
solution did not exceed .08%. Mitochondrial suspensions were incubated for
30 minutes at room temperature, and mitochondria were collected by
centrifugation at 12,500  g for 8 minutes. The presence of cytochrome c,
Figure 1. Antiproliferative effects of Bu, Clo, Flu, and Sor in FLT3-ITDepositive (A,B) and FLT3-wild type (C,D) AML cell lines. Cells were exposed to drugs alone, or in
combination, for 48 hours and analyzed by MTT and annexin V (Ann-V) assays. Results are expressed as the mean  SD of 3 independent experiments. PCR analysis
(E) shows the presence of mutated (FLT3-ITD) or wild type (WT-FLT3) FLT3 in the 4 cell lines. Bu or B, busulfan; Clo or C, clofarabine; Flu or F, ﬂudarabine; Sor,
sorafenib.
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chondrial pellet and of the supernatant.
Patient Cell Samples
Mononuclear cell samples from peripheral blood of AML patients with
FLT3-ITD mutations were collected using lymphocyte separation medium,
according to the manufacturer’s instructions. The puriﬁed cells were incu-
bated in Iscove’s modiﬁed Dulbecco’s medium supplemented with 10% FBS,
100 U/mL penicillin, and 100 mg/mL streptomycin with the indicated drugs.
Cells were analyzed after 48 hours of incubation. All cell collections and
pharmacological studies were performed according to a protocol approved
by the institutional review board of the University of Texas MD Anderson
Cancer Center.
Nucleic Acid Isolation and Detection of FLT3-ITD by PCR
Genomic DNA from mononuclear cell preparations was extracted using
Wizard Genomic DNA Puriﬁcation Kit (Promega, Madison, WI). The DNA
concentration was determined spectrophotometrically at 260 nm. PCR was
performed using primers speciﬁc for FLT3 exons 14 and 15 (14F, 50-
GCAATTTAGGTATGAAAGCCAGC-30 and 15R, 50-TTTCAGCATTTTGACGG-
CAACC-30), which cover the whole Juxtamembrane (JM) domain, ﬁrst part of
the TK-1 domain, the region where most of the reported ITDs are located
[26]. Ampliﬁcation was performed in a 50 mL reaction volume with 1 mg
genomic DNA, 10 pmol of each primer, 10 mmol deoxynucleoside triphos-
phate, 1.25 U Taq DNA polymerase. Denaturing, annealing, and extension
steps were performed at 94C for 30 seconds, 60C for 30 seconds, and 72C
for 40 seconds, respectively, for 30 cycles. There was an initial 2-minutedenaturation step at 94C and a ﬁnal extension step at 72C for 10 mi-
nutes. Ampliﬁcation products were analyzed on a 2% agarose gel stained
with ethidium bromide and samples showing PCR products longer than
330 bp (wt) were considered positive for FLT3-ITDs.
Statistical Analyses
All experiments were conducted at least 3 times, and results are
expressed as mean  SD. P values (Student t test) less than .05 were
considered statistically signiﬁcant.
RESULTS
Combinations of Bu, Clo, Flu, and Sor Exhibit Synergistic
Cytotoxicity and Induce Apoptosis in FLT3-ITDepositive
AML Cell Lines but not in FLT3-wt Cell Lines
Drug-associated effects were examined, alone and in
various combinations, on the proliferation of MV-4-11 cells.
Cells were exposed for 48 hours and analyzed by the MTT
assay. As shown in Figure 1A, exposure of MV-4-11 cells to
Bu, Clo, Flu, or Sor alone, or to 2-drug combinations BuþClo,
BuþFlu, and CloþFlu, did not signiﬁcantly affect cell prolif-
eration relative to the control at the drug concentrations
used. The combination of BuþCloþFlu resulted in w20% in-
hibition of cell proliferation. Addition of Sor to the Buþ
CloþFlu mixture further enhanced the inhibition of
A B
Figure 2. Drug combinations activate the DNA damage response and induce apoptosis. MV-4-11 cells were exposed to Bu, Clo, Flu, and Sor alone, or in combination,
for 48 hours and changes in the level and modiﬁcation of proteins involved in DNA damage response pathway (A) and apoptosis (B) were analyzed by Western blot.
Bu or B, busulfan; Clo or C, clofarabine; Flu or F, ﬂudarabine; Sor, sorafenib.
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MV-4-11 cell death were also examined with the Annexin V
assay (Roche). Exposure of cells to Bu, Clo, Flu, or Sor alone
did not induce apoptosis, and exposure to 2- or 3-drug
combinations BuþClo, BuþFlu, CloþFlu, and BuþCloþFlu
induced 5% to 10% apoptosis. Addition of Sor to the Buþ-
CloþFlu mixture signiﬁcantly enhanced apoptosis to
approximately 50%. Similar results were obtained when
another FLT3-ITDepositive AML cell line (MOLM 13) was
used (Figure 1B).
The antiproliferative effects of Bu, Clo, Flu, and Sor in
FLT3-wt THP-1 and KBM3/Bu2506 cells were also examined
by the MTT assay. No synergism attributable to the addition
of Sor was observed in cells exposed to the combination of
BuþCloþFluþSor (Figure 1C,D) even at higher drug concen-
trations (61.5 mM Bu, .02 mM Clo, 1.0 mM Flu, and 1500 nM
Sor) compared with those used for MV-4-11 (4.1 mM Bu, .01
mM Clo, 2.5 mM Flu, and 1 nM Sor) and MOLM 13 (4.1 mM Bu,
.01 mM Clo,1 mM Flu, and 5 nM Sor) cells.
Figure 1E demonstrates the presence of FLT3-ITD muta-
tions in MV-4-11 and MOLM 13 cells as suggested by longer
PCR product (w360 bp). PCR analysis of the RNA isolated
from THP-1 and KBM3/Bu2506 cells shows the presence of
wt FLT3 (shorter PCR product).2MeH3K4
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Figure 3. Drug exposures increase modiﬁcations of histones. MV-4-11 cells
were exposed to Bu, Clo, Flu, and Sor alone, or in combination, for 48 hours
and histone modiﬁcations were analyzed by Western blot. Bu or B, busulfan;
Clo or C, clofarabine; Flu or F, ﬂudarabine; Sor, sorafenib.Drug Combinations Activate DNA Damage Signaling
Pathway and Trigger Apoptosis
We previously showed activation of the DNA damage
response in AML and lymphoma cells exposed to combina-
tions of nucleoside analogs, DNA alkylating agents, and a
histone deacetylase inhibitor [20,21]. We, therefore, opted to
determine whether the BuþCloþFluþSor combination also
activates DNA damage response in MV-4-11 cells. As shown
in Figure 2A, increased g-H2AX levels were seen in cells
exposed to BuþFlu, CloþFlu, and BuþCloþFlu. The highest
level of g-H2AX was in cells exposed to BuþCloþFluþSor.
Another known indicator of DNA damage response is the
phosphorylation of SMC1. Exposure of cells to BuþCloþ-
FluþSor resulted in the highest level of phosphorylation of
SMC1 at Ser 957 (Figure 2A). P53 protein, which is involved
in cell cycle checkpoint activation, DNA repair regulation,
and apoptosis, was activated as indicated by its phosphory-
lation. Exposure of MV-4-11 cells to Bu, BuþClo, BuþFlu,
CloþFlu, BuþCloþFlu, or BuþCloþFluþSor all showed P53phosphorylation at Ser15 (Figure 2A). Taken together, these
results strongly suggest activation of the DNA damage
pathway in MV-4-11 cells exposed to BuþCloþFluþSor.
The observed activation of DNA damage response
(Figure 2A) may ultimately lead to death of cells through
variousmechanisms that include apoptosis. Indeed, exposure
of cells to BuþCloþFluþSor resulted in enhanced cleavage of
caspase 3, caspase 9, and poly(ADP-ribose) polymerase 1,
which all suggests activation of apoptosis (Figure 2B).Drug Combinations Increase Histone Modiﬁcations
Post-translational modiﬁcations of histone tails, espe-
cially acetylation and methylation on lysine residues,
contribute to chromatin relaxation, which may render the
genomic DNA more accessible to the effects of chemothera-
peutic agents. To test whether these drug combinations
would affect histones in FLT3-ITDepositive AML cells, MV-4-
11 cells were exposed to various drug combinations. As
shown in Figure 3, MV-4-11 cells that were exposed to Bu,
Clo, Flu, or Sor, or to any 2-drug combination, did not show
any signiﬁcant changes in the level of histone acetylation or
methylation, whereas exposure to BuþCloþFlu marginally
increased acetylation of histone 3 at Lys 4 (Figure 3). The
A B
Figure 4. Drug combinations inhibit tyrosine kinases and phosphorylation of their substrates. MV-4-11 cells were exposed to Bu, Clo, Flu, and Sor alone, or in
combination, for 48 hours and the activation by phosphorylation of tyrosine kinases (A) and changes in the status of their downstream substrates (B) were analyzed
by Western blot. Cyto, cytosolic fraction; Nuc, nuclear fraction; Bu or B, busulfan; Clo or C, clofarabine; Flu or F, ﬂudarabine; Sor, sorafenib.
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increased histone 3 acetylation and methylation. The results
strongly suggest induction of chromatin remodeling through
histone modiﬁcations when MV-4-11 cells were exposed to
BuþCloþFluþSor.Drug Combinations Inhibit Phosphorylation of FLT3-ITD
Target Kinases
FLT3-ITDmutations result in the constitutive activation of
the FLT3 kinase enzymatic activity and consequently activate
FLT3 kinase-dependent downstream proliferative signaling
pathways. These include the Ras/mitogen-activated protein
kinase (MAPK) kinase pathway, MAPK kinase (MEK)/extra-
cellular signal-regulated kinase pathway, and PI3K/AKT
pathway [27]. In addition, FLT3-ITDmay potently activate the
STAT5 pathway [28-30], resulting in the expression of its
target genes such as cyclin D1, c myc, and p21, which encode
proteins essential for cell growth [31,32]. Exposure of cells to
Bu, Clo, and Flu did not signiﬁcantly change the phosphor-
ylation level of FLT3, whereas exposure of cells to Sor alone
or 2- or 3-drug combinations decreased the phosphorylation
of FLT3 at Tyr 591 (Figure 4A). Addition of Sor to the Buþ
CloþFlu mixture further inhibited the phosphorylation of
FLT3. Exposure of cells to single agents or their combinations
all showed inhibition of MEK phosphorylation at Ser 217/221
(Figure 4A).
Another known substrate of the FLT3-ITD kinase activity
is AKT [33]. The level of AKT phosphorylation at Ser 473
decreased in cells exposed to BuþCloþFlu or BuþCloþ
FluþSor compared with control, a single drug, or 2-drug
combinations.
The FLT3-ITDeactivated STAT5 was signiﬁcantly dephos-
phorylated at Tyr 694 when cells were exposed to Sor alone
or BuþCloþFlu, and addition of Sor to BuþCloþFlu further
decreased the level of p-STAT5 (Figure 4B). The expression of
STAT5-regulated serine threonine kinase PIM2 decreased
when cells were exposed to Sor alone, and PIM2 wasfurther deregulated when the cells were exposed to Buþ
CloþFluþSor (Figure 4A). The level of STAT3 phosphorylation
(Ser 727) also decreased in cells exposed to BuþCloþFluþSor
(Figure 4B).
Taken all together, these results strongly suggest that
prosurvival FLT3-ITDeactivated tyrosine kinases were
inhibited when cells were exposed to BuþCloþFluþSor and
these inhibitory effects probably resulted in committing the
cells to apoptosis.Drug Combinations Trigger Mitochondrial Outer
Membrane Permeabilization and Induce Release of Death
Factors
Although activation of DNA damage response and inhi-
bition of tyrosine kinases could explain the observed drug-
induced apoptosis, we wanted to determine if exposure of
AML cells to BuþCloþFluþSor would also decrease the DJm,
a known indicator of apoptosis [34,35]. MV-4-11 cells were
exposed to Sor alone, BuþCloþFlu, or BuþCloþFluþSor for
48 hours. Sor alone exposure did not decrease mitochondrial
membrane potential, whereas BuþCloþFlu and BuþCloþ
FluþSor exposures signiﬁcantly decreased the mitochondrial
membrane potential by approximately 20% and 55%,
respectively (Figure 5A). The results suggest that addition of
Sor to BuþCloþFlu might have contributed to apoptosis
through activation of the intrinsic apoptotic pathway.
The observed changes in mitochondrial membrane po-
tential may have resulted in an alteration of the outer
mitochondrial membrane and led to release of death factors
(cytochrome c, SMAC/DIABLO, and AIF) that normally reside
in the mitochondria. These released death factors are known
to trigger other downstream events in the apoptotic cascade.
To test whether the drug combinations would indeed
directly cause death factor release from mitochondria
in vitro, MV-4-11 cell mitochondria were isolated and
exposed to Sor alone, BuþCloþFlu, or BuþCloþFluþSor for
30 minutes at room temperature followed by a cold
Figure 5. Drug exposures decrease the mitochondrial membrane potential and induce release of death factors from isolated mitochondria. MV-4-11 cells (A) were
exposed to 4.1 mM busulfan .01 mM, clofarabine, 2.5 mM ﬂudarabine,  1 nM sorafenib (Sor) for 48 hours and analyzed for changes in mitochondrial membrane
potential as described under Materials and Methods. Results are expressed as percentage of ﬂuorescence changes relative to the control (mean  SD of 3 independent
experiments). xP < .05 relative to control. yP < .05 relative to BCF-treated group. Isolated mitochondria (B) from MV-4-11 cells were exposed to Sor alone or to
BCF  Sor for 30 minutes at the concentration indicated above. B, busulfan; C, clofarabine; F, ﬂudarabine; Super, supernatant; Mito, mitochondria.
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SMAC/DIABLO, and AIF in the pellet and in the corresponding
supernatant were assessed. As shown in Figure 5B, the
combination of BuþCloþFluþSor promoted the release of
cytochrome c and AIF from isolated mitochondria. The
exposure of mitochondria to Sor alone or to BuþCloþFlu
promoted SMAC/DIABLO release, and addition of Sor to
BuþCloþFlu further enhanced this effect. The results suggest
that the BuþCloþFluþSor combination may induce
apoptosis through activation of the intrinsic apoptotic
pathway. Finally, these observations suggest that Bu, Clo, Flu,
and Sor directly interact with the mitochondrial membrane
and trigger release of proapoptotic factors. This interpreta-
tion is in agreement with the previously reported direct
binding of Clo metabolites to protein(s) in the mitochondrial
membrane [36].
Other important regulators of the apoptotic pathway are
the members of the BCL-2 family [37]. These proteins regu-
late permeabilization of the outer mitochondrial membraneA B
Figure 6. Analysis of the BCL-2 family members involved in mitochondrial outer m
busulfan, .01 mM clofarabine, 2.5 mM ﬂudarabine,  1 nM sorafenib (Sor) for 48 hours
450 mg was used to perform immunoprecipitation with antibody against MCL-1 (B) or
obtained immunoprecipitates were probed with antibodies against BIM and MCL-1 (B)
of each picture refer to the band density values. B, Busulfan; C, clofarabine; F, ﬂudarin response to apoptosis-inducing signals. To test if these
proteins are involved in the drug-induced permeabilization
of the outer mitochondrial membrane and contributed to
apoptosis, we exposedMV-4-11 cells to solvent (control), Sor,
BuþCloþFlu, or BuþCloþFluþSor for 48 hours. MCL-1 or
PUMA complexes were immunoprecipitated from cell ex-
tracts, followed by immunoblotting with antibodies against
other members of the BCL-2 family (Figure 6). Normal rabbit
IgG was used as a negative control in these experiments. The
level of MCL-1, a B cell lymphoma 2 family member involved
in cell survival and in the resistance to cytarabine and
daunorubicin [38], decreased in cells exposed to BuþCloþ-
FluþSor (Figure 6A), and the MCL-1eimmunoprecipitated
large and small isoforms of BIM (presumably MCL-1 bound)
likewise proportionally decreased (Figure 6B). The level of
proapoptotic PUMA protein increased in cells exposed to
BuþCloþFlu and BuþCloþFluþSor (Figure 6A), and the
PUMA-immunoprecipitated (presumably PUMA bound) BCL-
2 and MCL-1 proteins proportionally increased (Figure 6C).C
embrane permeabilization in MV-4-11 cells. Cells were exposed to 4.1 mM
. Cell lysates for immunoprecipitation were analyzed by Western blot (A) and
PUMA (C). IgG was used as a negative control for the immunoprecipitation. The
or antibodies against BCL-2, MCL-1, and PUMA (C). The numbers at the bottom
abine.
Table 1
Characteristics of Leukemia Patients Whose Cell Samples Were Used in the Study
Patient No. Source Age Gender Race Diagnosis Cytogenetics Treatment before Sampling
1 Peripheral blood 76 M White Relapsed AML FLT3-ITD Not available PLX 3397
2 Peripheral blood 69 F Black Relapsed/refractory AML, FLT3-ITD Not available 5-Azacitidine, PKC-412
3 Peripheral blood 52 F White Relapsed/refractory AML, FLT3-ITD 46, xx, t(3;4), 46, xx,
t(3;17), 46, xx, t(9;16)
Hydrea, Zyvox, Zosyn,
Cipro, Cancidas
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FluþSor combinations may promote apoptosis by decreasing
the total level of antiapoptotic BCL-2 and MCL-1 proteins
(Figure 6A) while enhancing their interaction with proapo-
ptotic PUMA protein (Figure 6C).BuþCloþFluþSor Combination Has Synergistic Effects in
Primary FLT3-ITDepositive Cell Samples from AML
Patients
To conﬁrm the potential clinical relevance of the observed
synergism of BuþCloþFluþSor in the FLT3-ITDepositive AML
cell line, we subsequently isolated genomic DNA from AML
patient cell samples and used it to assay FLT3-ITD by PCR.
Table 1 shows the demographic characteristics of the pa-
tients who provided leukemic cell samples used in this study
and Figure 7A shows the results of PCR analysis suggesting
the presence of wt FLT3 in a sample from patient 1 and
longer FLT3 gene fragments (FLT3-ITD) in samples from all 3
patients. Isolated mononuclear cells from blood samples of
AML patients with FLT3-ITD mutation were exposed to
Sor, BuþCloþFlu, or BuþCloþFluþSor. Cytotoxicity assays
showed the efﬁcacy of combined BuþCloþFluþSor
(Figure 7B) and immunoblot analysis showed decreased
phosphorylation of FLT3 in cells exposed to Sor alone or
BuþCloþFlu, which further decreased in cells exposed to
BuþCloþFluþSor (Figure 7C), consistent with the previously
shown decreased phosphorylation of FLT3 in MV-4-11 cells
(Figure 4A). Phosphorylation of P53 was observed in cells
exposed to BuþCloþFlu or BuþCloþFluþSor, except in cells
from patient 2, who harbored mutated P53 (arrow, lower-
molecular weight). The phosphorylation of histone 2AX
increased in cells exposed to Sor (patient 2) or BuþCloþFlu
(patients 1 to 3), and was further enhanced in cells exposed
to BuþCloþFluþSor, suggesting robust activation of the DNA
damage response pathway. The elevated baseline level of g-Figure 7. Analysis of mononuclear cells from the peripheral blood of 3 AML patient
speciﬁc primers for FLT3-ITD (A). Mononuclear cells were exposed to the indicated
binations for 48 hours and analyzed for cell proliferation and apoptosis by the MTT an
PARP1 were determined by Western blot (C). Patient (Pt) number is indicated. BCF, bus
mM Flu, and 1 nM Sor.H2AX in patient 2 could possibly be due to other drugs the
patient was taking at the time of blood sampling. The syn-
ergistic activity of BuþCloþFluþSor in these cell samples is
further supported by the observed increase in cleavage of
PARP1, a marker of apoptosis (Figure 7C).DISCUSSION
When the multikinase inhibitor sorafenib (Sor) was
combinedwith nucleoside analogs (Clo and Flu) and the DNA
alkylating agent Bu, the combination exerts synergistic
cytotoxicity in FLT3-ITDemutated AML cell lines and pri-
mary, patient-derived cell samples with similar FLT3-ITD
mutations, whereas notably, no such synergy was detected
in AML cells who possess only wt FLT3. In addition to the
expected Sor-associated inhibition of tyrosine kinases, the
observed cytotoxicity was achieved through activation of
DNA damage response and induction of chromatin remod-
eling through altered methylation and acetylation status of
histones. Induced activation of caspases 3 and 9, increased
expression of the proapoptotic protein PUMA, and decreased
expression of MCL-1 may also contribute to cytotoxicity.
Finally, the changes in the level of PUMA andMCL-1 proteins
may have decreased mitochondrial membrane potential and
induced release of death factors (cytochrome c, SMAC/DIA-
BLO, and AIF) from the mitochondria, further contributing to
cell death.
Clo and Flu may directly affect mitochondria by disrupt-
ing membrane integrity, leading to release of cytochrome c
and AIF [36]. These nucleoside analogs have been demon-
strated to cause DNA damage and induce P53 phosphoryla-
tion, leading to release of cytochrome c and activation of the
intrinsic apoptotic machinery [39-42]. Indeed, AML cells
exposed to the BuþCloþFluþSor combination showed acti-
vation of apoptosis, which was consistent with previously
reported effects of Sor in leukemia cell lines [43]. Apoptosiss with FLT3-ITD mutations. FLT3-ITD mutations were conﬁrmed by PCR with
concentrations of Sor, busulfanþclofarabineþﬂudarabine (BCF), or their com-
d Annexin V assays, respectively (B). The levels of p-FLT3, p-P53, g-H2AX, and
ulfanþclofarabineþﬂudaribine; BCFS, BCFþSor. 1X ¼ 4.1 mM Bu, .01 mM Clo, 2.5
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phorylation (Figure 4B) [44] and downregulation of MCL-1
(Figure 6A) [45,46]. Further, Sor may have blocked both
basal and ligand dependent FLT3-mediated tyrosine auto-
phosphorylation (Figure 4A) as well as extracellular
signal-regulated kinase 1/2 and STAT5 phosphorylation
(Figure 4B) [43]. Taken together, the observations assist in
mechanistically explaining how Sor synergistically enhances
the BuþCloþFlueinduced cytotoxicity.
Sor was previously shown to induce apoptosis via
BIM-mediated activation of the intrinsic apoptotic pathway
in the AML cell lines U937, HL60, KG-1, and OCI-AML3 [6], all
of which express wt FLT3. In our cell line model, we observed
an increase in the level of proapoptotic BIM and PUMA
proteins when the cells were exposed to BuþCloþFluþSor
(Figure 6A). The interaction of PUMA with BCL-2 and MCL-1
increased when cells were exposed to BuþCloþFlu or Buþ-
CloþFluþSor (Figure 6C). Such increased protein interaction
with PUMA is known to antagonize the antiapoptotic activity
of BCL-2 and MCL-1 [47] and may partially explain the
observed drug-induced activation of apoptosis.
In summary, the multikinase inhibitor Sor synergistically
increases the cytotoxicity achieved with nucleoside analogs
and the DNA alkylating agent Bu in 2 FLT3-ITDepositive AML
cell lines, as well as in FLT3-ITDepositive patient-derived
leukemia cells, but not in cells that only have wt FLT3. Our
results can be used to mechanistically justify the incorpora-
tion of this multikinase inhibitor(s) in an enhanced Buþ-
CloþFluebased pretransplantation conditioning regimen for
patients with AML who carry the FLT3-ITD mutation. These
patients are at high risk for recurrent AML, even after allo-
geneic stem cell transplantation. Therefore, we suggest that
our new experimental data may be used as a model for how
to move from a standardized pretransplantation condition-
ing program to 1 that incorporates individualized disease
information, aimed at optimizing treatment outcome in an
early era of personalized medicine applied in stem cell
transplantation.ACKNOWLEDGMENTS
This work was supported in part by a grant from the
National Institutes of Health (CCSG Core CA16672), the Ste-
phen L. and Lavinia Boyd Fund for Leukemia Research, and by
funds donated by grateful patients.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Financial disclosure: The authors have nothing to disclose.REFERENCES
1. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical signiﬁcance of the
FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:
1901-1908.
2. Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multikinase
inhibitor, suppresses the growth of leukemia cells with FLT3 mutations
or T315I-mutated BCR/ABL translocation. Blood. 2009;114:1607-1617.
3. Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leuke-
mia: a record of trials and tribulations. Oncologist. 2011;16:1162-1174.
4. Knapper S. The clinical development of FLT3 inhibitors in acute
myeloid leukemia. Expert Opin Investig Drugs. 2011;20:1377-1395.
5. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3
in acute myeloid leukemia. Leukemia. 2012;26:2176-2185.
6. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of
sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100:
184-198.
7. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib
in FLT3-ITD-positive acute myeloid leukemia: sustained regression
before and after allogeneic stem cell transplantation. Blood. 2009;113:
6567-6571.8. Schroeder T, Zohren F, Saure C, et al. Sorafenib treatment in 13 patients
with acute myeloid leukemia and activating FLT3 mutations in com-
bination with chemotherapy or as monotherapy. Acta Haematol. 2010;
124:153-159.
9. Winkler J, Rech D, Kallert S, et al. Sorafenib induces sustained molec-
ular remission in FLT3-ITD positive AML with relapse after second
allogeneic stem cell transplantation without exacerbation of acute
GVHD: a case report. Leuk Res. 2010;34:e270-e272.
10. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in
patients with refractory or relapsed acute leukemias. Haematologica.
2011;96:62-68.
11. Mohan BP, How GF, Loh Y, Linn YC. Sorafenib monotherapy gives
sustainable suppression of FLT3 clone in untreated patients with FLT3-
internal tandem duplication positive acute myeloid leukaemia. Br J
Haematol. 2012;157:131-132.
12. Röllig C, Brandts C, Shaid S, et al. Survey and analysis of the efﬁcacy and
prescription pattern of sorafenib in patients with acute myeloid leu-
kemia. Leuk Lymphoma. 2011;53:1062-1067.
13. Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-
positive acute myeloid leukemia relapsing after allogeneic stem cell
transplantation with sorafenib. Biol Blood Marrow Transplant. 2011;17:
1874-1877.
14. Sorà F, Chiusolo P, Metafuni E, et al. Sorafenib for refractory FMS-
like tyrosine kinase receptor-3 (FLT3/ITDþ) acute myeloid leuke-
mia after allogenic stem cell transplantation. Leuk Res. 2011;35:
422-423.
15. Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(þ) acute
myeloid leukemia: favorable initial outcome and mechanisms of sub-
sequent nonresponsiveness associated with the emergence of a D835
mutation. Blood. 2012;119:5133-5143.
16. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as
a therapeutic target in human acute myeloid leukaemia. Nature. 2012;
485:260-263.
17. Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic
and pharmacodynamic study of the multikinase inhibitor sorafenib in
combination with clofarabine and cytarabine in pediatric relapsed/re-
fractory leukemia. J Clin Oncol. 2011;29:3293-3300.
18. Fontanelli G, Rocco M, Caracciolo F, et al. Sorafenib as monotherapy or
in association with cytarabine and clofarabine for the treatment of
relapsed/refractory FLT3 ITD-positive advanced acute myeloid leuke-
mia. Clin Lymphoma Myeloma Leuk. 2014;14:e13-17.
19. Valdez BC, Li Y, Murray D, et al. The synergistic cytotoxicity of clofar-
abine, ﬂudarabine and busulfan in AML cells involves ATM pathway
activation and chromatin remodeling. Biochem Pharmacol. 2011;81:
222-232.
20. Valdez BC, Murray D, Nieto Y, et al. Synergistic cytotoxicity of the DNA
alkylating agent busulfan, nucleoside analogs and suberoylanilide
hydroxamic acid in lymphoma cell lines. Leuk Lymphoma. 2012;53:
973-981.
21. Song G, Valdez BC, Li Y, et al. The histone deacetylase inhibitor SAHA
sensitizes acute myeloid leukemia cells to a combination of nucleoside
analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma. 2014;
55:1625-1634.
22. Andersson BS, Valdez BC, de Lima M, et al. Clofarabine  ﬂudarabine
with once daily i.v. busulfan as pretransplant conditioning therapy for
advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant.
2011;17:893-900.
23. Valdez BC, Murray D, Ramdas L, et al. Altered gene expression in
busulfan-resistant human myeloid leukemia. Leuk Res. 2008;32:
1684-1697.
24. Kasugai S, Hasegawa N, Ogura H. A simple in vitro cytotoxicity test
using the MTT (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) colorimetric assay: analysis of eugenol toxicity on dental
pulp cells (RPC-C2A). Jpn J Pharmacol. 1990;52:95-100.
25. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution
of plasma membrane phosphatidylserine is a general feature of
apoptosis regardless of the initiating stimulus: inhibition by over-
expression of Bcl-2 and Abl. J Exp Med. 1995;182:1545-1556.
26. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-
RAS gene mutations in acute myeloid leukaemia. Blood. 1999;93:
3074-3080.
27. Gilliland DG, Grifﬁn JD. The roles of FLT3 in hematopoiesis and leu-
kemia. Blood. 2002;100:1532-1542.
28. Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid tran-
scription factors and induction of STAT response genes by AML speciﬁc
Flt3 mutations. Blood. 2003;101:3164-3173.
29. Choudhary C, Schwable J, Brandts C, et al. AML-associated Flt3 kinase
domain mutations show signal transduction differences compared
with Flt3 ITD mutations. Blood. 2005;106:265-273.
30. Grundler R, Miething C, Thiede C, et al. FLT3-ITD and tyrosine kinase
domain mutants induce 2 distinct phenotypes in a murine bone
marrow transplantation model. Blood. 2005;105:4792-4799.
31. Calo V, Migliavacca M, Bazan V, et al. STAT proteins: from normal
control of cellular events to tumorigenesis. J Cell Physiol. 2003;197:
157-168.
G. Song et al. / Biol Blood Marrow Transplant 20 (2014) 1687e1695 169532. Takahashi S, Harigae H, Kaku M, et al. Flt3 mutation activates
p21(WAF1/CIP1) gene expression through the action of STAT5. Biochem
Biophys Res Commun. 2004;316:85-92.
33. Gilliland DG, Grifﬁn JD. Role of FLT3 in leukemia. Curr Opin Hematol.
2002;9:274-281.
34. Vayssiere JL, Petit PX, Risler Y, Mignotte B. Commitment to apoptosis is
associated with changes in mitochondrial biogenesis and activity in cell
lines conditionally immortalized with simian virus 40. Proc Natl Acad
Sci U S A. 1994;91:11752-11756.
35. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced
neuronal death: a succession of necrosis or apoptosis depending on
mitochondrial function. Neuron. 1995;15:961-973.
36. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce
programmed cell death in chronic lymphocytic leukemia cells by
damaging the DNA and by directly affecting the mitochondria. Blood.
2000;96:3537-3543.
37. Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in
apoptosis. Nat Rev Cancer. 2008;8:121-132.
38. Kasper S, Breitenbuecher F, Heidel F, et al. Targeting MCL-1 sensitizes
FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J.
2012;2:e60.
39. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphor-
ylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325-334.
40. Evan G, Littlewood T. A matter of life and cell death. Science. 1998;281:
1317-1322.41. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for
the in vitro activation of the apoptosis protein-activating factor-1-
mediated caspase pathway. J Biol Chem. 2000;275:29-34.
42. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Spontaneous and
drug-induced apoptosis is mediated by conformational changes of Bax
and Bak in B-cell chronic lymphocytic leukemia. Blood. 2002;100:
1810-1816.
43. Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in
FLT3-driven leukemic cells. Leukemia. 2007;21:439-445.
44. Zhao W, Zhang T, Qu B, et al. Sorafenib induces apoptosis in HL60 cells
by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer
Drugs. 2011;22:79-88.
45. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhib-
itor sorafenib induces apoptosis in highly imatinib mesylate-
resistant bcr/ablþ human leukemia cells in association with
signal transducer and activator of transcription 5 inhibition and
myeloid cell leukemia-1 down-regulation. Mol Pharmacol. 2007;72:
788-795.
46. Fecteau JF, Bharati IS, O’Hayre M, et al. Sorafenib-induced apoptosis of
chronic lymphocytic leukemia cells is associated with downregulation
of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med. 2012;
18:19-28.
47. Bouillet P, Strasses A. BH3-only proteins - evolutionarily conserved
proapoptotic Bcl-2 family members essential for initiating pro-
grammed cell death. J Cell Sci. 2002;115:1567-1574.
